Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial

被引：0
|
作者：
Gao, Qinglei
Wang, Jing
Xu, Qin
Tang, Ying
Zhang, Jieqing
Chang, Baoping
Xia, Bairong
Duan, Wei
Wang, Danbo
Zhu, Lijing
An, Ruifang
Zhang, Guonan
Tang, Yaling
Huang, Jianli
Zhang, Xiang
Qiu, Hui
Ji, Wenting
Li, Li
Zhu, Jianqing
Ma, Ding
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT079
引用
收藏
页数：3
相关论文
共 50 条
  • [21] First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+locally advanced or metastatic urothelial carcinoma (UC) in Asian patients
    Ye, D.
    Liu, J.
    Zhou, A.
    Zou, Q.
    Li, H.
    Fu, C.
    Hu, H.
    Huang, J.
    Zhu, S.
    Jin, J.
    Ma, L.
    Guo, J.
    Xiao, J.
    Park, S. H.
    Zhang, D.
    Qiu, X.
    Bao, Y.
    Zhang, L.
    Shen, W.
    Feng, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 367 - 367
  • [22] Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
    Rogado, J.
    Romero Laorden, N.
    Sanchez Torres, J. M.
    Ramos-Levi, A.
    Pacheco-Barcia, V. E.
    Ballesteros Garcia, A. I.
    Arranz, R.
    Lorenzo, A.
    Gullon, P.
    Garrido, A.
    Serra, J. M.
    Donnay, O.
    Adrados, M.
    Costas, P.
    Aspa, J.
    Alfranca, A.
    Mondejar, R.
    Colomer Bosch, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Yuegang Li
    Yuwei Du
    Chi Xue
    Pei Wu
    Nan Du
    Guolian Zhu
    Huimian Xu
    Zhi Zhu
    BMC Gastroenterology, 22
  • [24] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Li, Yuegang
    Du, Yuwei
    Xue, Chi
    Wu, Pei
    Du, Nan
    Zhu, Guolian
    Xu, Huimian
    Zhu, Zhi
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [25] GLS-010 (ZIMBERELIMAB), A NOVEL FULLY HUMAN ANTI-PD-1 MAB IN CHINESE PATIENTS WITH RECURRENT/METASTATIC CERVICAL CANCER: RESULTS FROM A MULTICENTER, OPEN-LABEL, SINGLE-ARM PHASE II TRIAL
    Wu, X.
    Xia, L.
    Zhou, Q.
    Zhu, J.
    Wang, K.
    Chen, J.
    Huang, Y.
    Kurb, G.
    Chang, B.
    Zhao, W.
    Wang, X.
    Yang, Y.
    Lin, Z.
    Luo, X.
    Lou, G.
    Wang, C.
    Wang, J.
    Meng, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A147 - A147
  • [26] Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
    Hanker, L. C.
    Oaknin, A.
    Tinker, A.
    Gilbert, L.
    Samouelian, V
    Mathews, C.
    Brown, J.
    Guo, W.
    Danaee, H.
    Im, E.
    Sabatier, R.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E220 - E220
  • [27] Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
    Shi, Shuling
    Li, Bingyan
    Zhou, Pengcheng
    Chen, Linhui
    Li, Huizhen
    Wang, Yingyi
    Deng, Xiaoyu
    Dang, Qianqian
    Wu, Jingjing
    Zha, Boya
    Li, Peihong
    Zheng, Yingjuan
    Yang, Daoke
    CANCER MEDICINE, 2024, 13 (14):
  • [28] Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
    Oaknin, A.
    Tinker, A. V.
    Gilbert, L.
    Samouelian, V.
    Mathews, C. A.
    Brown, J.
    Guo, W.
    Danaee, H.
    Im, E.
    Sabatier, R.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 6 - 6
  • [29] A PHASE II CLINICAL TRIAL OF IMMUNOTHERAPY WITH ANTI-PD-1 ANTIBODY (NIVOLUMAB) IN ADVANCED/RELAPSED, PLATINUM-RESISTANT OVARIAN CANCER
    Hamanishi, J.
    Mandai, M.
    Matsumura, N.
    Abiko, K.
    Baba, T.
    Yamaguchi, K.
    Ueda, M.
    Horikawa, N.
    Murakami, R.
    Koshiyama, M.
    Konishi, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 400 - 401
  • [30] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
12345